Symbols

CODX

Co-diagnostics·NASDAQ

--(--)

CODX fundamentals

CODX Q4 2025 Earnings Preview

Co-diagnostics (CODX) expects to report earnings on Mar 31, 2026, with estimated revenue of 125.88K (YoY -15.70%), and EPS at -3.6 (YoY +66.67%).

Revenue estimate / YoY

125.88K

-15.70%

EPS estimate / YoY

-3.6

+66.67%

Report date

Mar 31, 2026

CODX Earnings Call Summary for Q4,2025

Global Expansion: India manufacturing hub established, South Asia market expansion to $13B.
Clinical Progress: 1,200 patient trials, FDA submission for flu/RSV panel.
Financial Discipline: $11.9M cash, down from $29.7M.
Risk: Reliance on grant funding.
Opportunity: AI-driven diagnostics development.

Earnings

EPS

Revenue

Revenue & Expenses

CODX has released its 2025 Q4 earnings report, with revenue of 263.92K, reflecting a YoY change of 76.74%, and net profit of -25.75M, showing a YoY change of -133.39%. The Sankey diagram below clearly presents CODX's revenue sources and cost distribution.

Key Indicators

Co-diagnostics (CODX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Co-diagnostics (CODX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Co-diagnostics (CODX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Co-diagnostics (CODX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown